Phase 2
Completed N=20
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Source: ClinicalTrials.gov NCT00301067 ↗Enrolled (actual)
20
Serious AEs
45.0%
Results posted
Dec 2018
Primary outcomePrimary: Number and Frequency of Dose Limiting Toxicities (DLTs) With High-dose Calcitriol in Combination With Temozolomide — 0; 0; 0 DLT
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Calcitriol may help temozolomide kill more tumor cells by making them more sensitive to the drug. Calcitriol may also stop the growth of melanoma by blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the best dose of calcitriol, the side effects of calcitriol when given together with temozolomide, and to see how well they work in treating patients with metastatic stage IV melanoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number and Frequency of Dose Limiting Toxicities (DLTs) With High-dose Calcitriol in Combination With Temozolomide |
0; 0; 0 | — |
| PRIMARY Number of Patients With Toxicity |
1; 0; 0; 1; 1; 0 | — |
| SECONDARY Tumor Response |
0; 2; 1; 17 | — |
| SECONDARY The Relationship Between Vitamin D-receptor Gene Polymorphisms and Tumor Response |
— | — |
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed malignant melanoma
- Any primary tumor site
- Stage IV disease
- CNS metastases allowed
- Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension as ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- Must have had at least 1 prior systemic therapy
- Negative pregnancy test
- Fertile patients must use effective contraception
- Patients with no prior systemic therapy are eligible provided they are not candidates for high-dose interleukin-2
- Recovered from all toxic effects of prior therapy
- More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or immunotherapy
- More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or immunotherapy
- Fertile patients must use effective contraception
Exclusion Criteria
- Life expectancy less than 4 months
- known HIV positivity
- evidence of active infection requiring antibiotic therapy
- other malignancy within the past 5 years except surgically resected basal cell or squamous cell skin cancer
- significant medical disease which, in the opinion of the investigator, may interfere with study completion
- pregnant or nursing
- Negative pregnancy test
- prior temozolomide or dacarbazine
- investigational agent within 4 weeks prior to study entry
- concurrent magnesium-containing antacids, digitalis, bile-resin binding drugs, or calcium supplements
Data sourced from ClinicalTrials.gov (NCT00301067). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.